Narumol Silpa-ArchaSunatra NitayavardhanaKanchalit ThanomkittiLeena ChularojanamontriSupenya VarothaiChanisada WongpraparutMahidol University2018-12-112019-03-142018-12-112019-03-142016-12-01Dermatologica Sinica. Vol.34, No.4 (2016), 177-1792223330X102781172-s2.0-84994804659https://repository.li.mahidol.ac.th/handle/20.500.14594/40971© 2016 Topical tacrolimus has demonstrated efficacy in vitiligo. This study compared the efficacy and safety of 0.1% tacrolimus ointment with 0.1% mometasone furoate cream in adult vitiligo. We enrolled patients with symmetrical, nonacral vitiligo, and the patients on each side were randomized to receive either 0.1% tacrolimus ointment or 0.1% mometasone furoate cream, applied twice daily for 6 months. Repigmentation outcome at 6 months was compared with baseline. Of 18 cases, 22% and 33% in tacrolimus and mometasone groups, respectively, displayed more than 50% repigmentation (p > 0.05). Telangiectasia was presented in one-third of cases on the mometasone-treated side. Both treatments were effective in vitiligo; however, 0.1% tacrolimus ointment has fewer adverse effects.Mahidol UniversityMedicineArticleSCOPUS10.1016/j.dsi.2016.05.005